These results suggest that blocking IGF1R signaling during gemcitabine treatment could prevent chemotherapy-induced CD44 expression or isoform switching and increase pancreatic cancer response to chemotherapy. This evidence concerns the gene CD44 and familial pancreatic carcinoma.